Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Commences PI of ADC DS-6000 in US
February 4, 2021
- Eisai’s April-December Profits Slip on Aggressive Investments
February 4, 2021
- US FDA Accepts NDA for Santen/Ube's Glaucoma Drug
February 4, 2021
- Eisai Neurology Chief Says Partners Continue to Stand Behind Aducanumab
February 4, 2021
- Mitsubishi Tanabe’s April-December Sales Down 2.4% over Price Cuts, Generic Erosion
February 4, 2021
- Mitsubishi Tanabe’s Dyskinesia Med Smashes Goal in Japan PII/III, Eyes Submission in FY2021
February 4, 2021
- Ono Earns Japan, Asia Rights to Ribon’s PARP7 Inhibitor
February 3, 2021
- Internal Probe Finds No Physical Evidence, Testimony in Ex-Sandoz Rep’s Residual Drug Resale Case
February 3, 2021
- Yoshindo Files Nesp Biosimilar in Japan
February 3, 2021
- Shonan iPark Begins Pilot Study to Build iPS Cell Donation Platform
February 3, 2021
- Hokkaido Univ., PuREC, Mochida Launch Joint Research on Novel Treatment for Spine-Related Diseases
February 3, 2021
- Nichi-Iko Closes Acquisition of Teva Takeda’s Generic Biz
February 2, 2021
- Ono Logs 4.3% Sales Growth in April-December, Opdivo Jumps
February 2, 2021
- Astellas Returns Rights to Prostate Cancer Med to US Firm
February 2, 2021
- Sumitomo Dainippon to Invest Up to US$20 Million in US Venture Fund Focused on Digital Health
February 2, 2021
- Shuhei Sekiguchi to Become Janssen Japan Chief on March 1
February 2, 2021
- Sosei Ties Up with UK CRO to Identify Lead Compounds in Neurological Diseases
February 2, 2021
- Shionogi Sees Double-Digit Sales Decline in April-December as Infectious Disease Meds Suffer
February 2, 2021
- Astellas Sees Growth of Evrenzo after 14-Day Prescription Limit Lifted: EVP
February 1, 2021
- FunPep Initiates Development of New IL-23 Antibody-Inducing Peptide
February 1, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…